- Home
- BTTC vs GNPX Comparison
BTTC vs GNPX Comparison
Compare BTTC & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTTC | GNPX |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 11.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | BTTC | GNPX |
|---|---|---|
| Price | $0.93 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.5K | ★ 232.3K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $0.14 |
| 52 Week High | $11.22 | $12.97 |
Technical Indicators
Market Signals| Indicator | BTTC | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 28.11 | 21.52 |
| Support Level | N/A | $0.16 |
| Resistance Level | $1.41 | $2.12 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.06 | 4.79 |
Price Performance
Historical ComparisonAbout BTTC Black Titan Corporation Ordinary Shares
Black Titan Corp provides human resource and payroll consulting, software implementation, and training solutions using PeopleSoft platforms. The company's revenue is mainly derived from the provision of HCM solutions, followed by the provision of IT staff augmentation, outsourcing and consulting services.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).